**Abstract**

**Background:** Effective treatments to alleviate depression in Alzheimer's disease (AD) have been scarce.

**Objective:** To investigate the efficacy and tolerability of escitalopram in the treatment of depression with AD.

**Methods:** In this 12-week randomized, double-blind, placebo-controlled cohort study with open-label, 12-week extension, subjects over 50 years of age, with AD defined by NINCDS-ADRDA criteria, and depression defined by Olin's provisional diagnostic criteria for depression of AD, were enrolled. The main outcome measure was the Cornell Scale for Depression in Dementia (CSDD), and various other measures of depression and cognition were repeated.

**Results:** 91 subjects were screened, and 84 were randomized. (n = 42 for both groups). Twenty-four subjects (29%) were unable to finish the study, yielding a per protocol population of 60 subjects (study group: n = 27; placebo group: n = 33). At 12 weeks, mean CSDD scores were lower in the study group, and scores decreased faster, but the differences were not statistically significant. However, when subjects with 'definite major depression' (baseline CSDD score ≥ 18) were selected and compared (n = 6 for each group), differences were more definite. The main difference was in the 'cyclic functions' category. Significant differences were not observed among secondary outcome measures. The number of treatment-related adverse-events (AE) did not differ between groups (p=0.83) and no serious treatment-related AE were observed.

Conclusion: The use of escitalopram was well tolerated in depressive dementia patients, and it also reduced depressive symptoms faster that placebo in subjects with definite major depression. Future studies focusing on subjects with more severe levels of depression, and with more statistical power, will be needed.
